



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated November 29, 2019

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Receipt of Establishment Inspection Report (EIR) from US FDA -Reg.

Ref: Our letter dated 22nd August 2019 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Please be informed that, US FDA has issued Establishment Inspection Report (EIR) for Granules Pharmaceuticals, Inc. facility, a wholly-owned foreign subsidiary of the Company located in Chantilly, Virginia, USA.

This facility was inspected by US FDA in August 2019 and there were two (2) minor observations during the inspection. The company has responded to the observations within the stipulated timeframe.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

For GRANULES INDIA LIMITED

Chaitanya Tummala

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**